166 related articles for article (PubMed ID: 35419000)
1. Quantitative Comparison of the Clinical Efficacy of 6 Classes Drugs for IgA Nephropathy: A Model-Based Meta-Analysis of Drugs for Clinical Treatments.
Yu J; Luo J; Zhu H; Sui Z; Liu H; Li L; Zheng Q
Front Immunol; 2022; 13():825677. PubMed ID: 35419000
[TBL] [Abstract][Full Text] [Related]
2. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
3. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
4. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
[TBL] [Abstract][Full Text] [Related]
5. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.
Zhang J; Lu X; Feng J; Li H; Wang S
Biomed Res Int; 2021; 2021():9171715. PubMed ID: 34901280
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
7. Sodium-sensitive variability of the antiproteinuric efficacy of RAS inhibitors in outpatients with IgA nephropathy.
Suzuki T; Miyazaki Y; Shimizu A; Ito Y; Okonogi H; Ogura M; Utsunomiya Y; Kawamura T; Hosoya T
Clin Nephrol; 2009 Oct; 72(4):274-85. PubMed ID: 19825333
[TBL] [Abstract][Full Text] [Related]
8. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Park HC; Xu ZG; Choi S; Goo YS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Nephrol Dial Transplant; 2003 Jun; 18(6):1115-21. PubMed ID: 12748343
[TBL] [Abstract][Full Text] [Related]
9. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.
Liu LJ; Lv JC; Shi SF; Chen YQ; Zhang H; Wang HY
Am J Kidney Dis; 2012 Jan; 59(1):67-74. PubMed ID: 22019331
[TBL] [Abstract][Full Text] [Related]
10. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
11. Drug Therapies for Patients with IgA Nephropathy: A Network Meta-analysis of Randomized Clinical Trials.
Sridharan K; Sivaramakrishnan G
Curr Clin Pharmacol; 2020; 15(2):132-144. PubMed ID: 31870272
[TBL] [Abstract][Full Text] [Related]
12. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Ishikura K; Hataya H; Honda M; Nozu K; Iijima K; Shima Y; Yoshikawa N;
Pediatr Nephrol; 2015 Jun; 30(6):961-7. PubMed ID: 25487669
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
Shima Y; Nakanishi K; Kaku Y; Ishikura K; Hataya H; Matsuyama T; Honda M; Sako M; Nozu K; Tanaka R; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2018 Nov; 33(11):2103-2112. PubMed ID: 29987456
[TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety for the treatments despite optimized renin-angiotensin system blockade among IgA nephropathy patients at high-risk of disease progression: A network meta-analysis of randomized controlled trials.
Tan Q; Xue H; Ni X; Fan L; Du W
Eur J Intern Med; 2023 Aug; 114():66-73. PubMed ID: 37179138
[TBL] [Abstract][Full Text] [Related]
17. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
[TBL] [Abstract][Full Text] [Related]
19. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
Ferraro PM; Ferraccioli GF; Gambaro G; Fulignati P; Costanzi S
Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
